Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking.
Specific areas of discussion will include:
- Targets for novel drug development
- Toxicology studies and considerations
- The dosage debate and new evidence
- Second generation psychedelic drug design
- FDA regulatory guidance
The speaker panel consists of an impressive line-up of leaders and dignitaries who will share important insights and strategies on a number of industry topics. This includes the latest discoveries, psychedelic therapeutics, and clinical trials, offering a fresh perspective and critical knowledge to attendees.
Speaker topics will cover:
- Clinical Trial Design
- Legal Issues
- Intellectual Property
- Regulatory Guidance
- Psychedelic Drug Delivery
- Commercialization
- Emerging Preclinical Science
- New Clinical Data
This conference offers an excellent forum for newcomers as well as veterans for the discovery and exchange of knowledge in the world of psychedelics and therapeutics.
The event commences with opening remarks from the chairperson, Peter Hendricks, Ph.D., Professor, Department of Psychiatry, University of Alabama Birmingham. Attendees will get answers to some vital issues related to ways of optimizing psychedelic trials and scaling trail delivery while still being consistent. Other important topics include discussions on studies being conducted for the treatment of Schizophrenia, postpartum depression, distress in cancer, and more.
After the morning refreshment break, the conference will resume with a panel discussion navigating the challenges in research and compliance with the Federal Analogue Act.
The conference is being held at the luxurious Revere Hotel Boston Common, 200 Stuart Street, Boston, MA (www.reverehotel.com), described as “Shaped by local culture and the rebellious, independent spirit of Boston, Revere Hotel Boston Common is a downtown refuge for the adventurous and curious. Immerse yourself in authentic local experiences at our original Back Bay hotel, located steps from Boston’s Theater District, Newbury Street and Copley Square.”
To register and learn more, please visit https://ibn.fm/FCMNc.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
